Avicanna (TSE:AVCN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avicanna has successfully completed its first delivery of proprietary topical products to a multinational pharmaceutical company, marking a significant step in its European commercial expansion. The products, which include CBD and CBG-based formulations, are set to launch in six European countries in 2025, leveraging the pharmaceutical company’s established infrastructure.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.